GH1 and acromegaly: For pasireotid (acromegaly) the PEP was biochemical control (defined as a combination of reduction of the mean growth hormone [GH] level below 2.5 μg/l and normalisation of the age- and sex-adjusted insulin-like growth factor 1 [IGF-1] level after 24 weeks).